LGD-6972 是口服有活性的胰高血糖素受体选择性拮抗剂，能够用于研究 2 型糖尿病。

LGD-6972 is an antagonist of glucagon receptor.

LGD-6972 is well tolerated at the doses tested without dose-related or clinically meaningful changes in clinical laboratory parameters. No subject experiences hypoglycaemia.LGD-6972 has linear plasma pharmacokinetics consistent with once daily dosing that is comparable in healthy and T2DM subjects.?Dose-dependent decreases in fasting plasma glucose are observed in all groups with a maximum of 3.15 mM (56.8 mg/dL) on day 14 in T2DM subjects.?LGD-6972 also reduces plasma glucose in the postprandial state.?Dose-dependent increases in fasting plasma glucagon are observed, but glucagon levels decrease and insulin levels increase after an oral glucose load in T2DM subjects.

1207989-09-0

C43H46N2O5S

702.9

DMSO:31 mg/mL (44.10 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years